Compounds > Glycyl-H-1152
Page last updated: 2024-08-02 22:55:25

Glycyl-H-1152

Description

Glycyl-H-1152 : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID11976582
CHEMBL ID3348907
SCHEMBL ID678400
CHEBI ID185944

Synonyms (15)

Synonym
2-amino-1-[(3s)-3-methyl-4-(4-methylisoquinolin-5-yl)sulfonyl-1,4-diazepan-1-yl]ethanone
rho kinase inhibitor iv
2-amino-1-[(3s)-3-methyl-4-(4-methylisoquinolin-5-yl)sulonyl-1,4-diazepan-1-yl]ethanone
glycyl-h-1152
CHEBI:185944
NCGC00346802-01
913844-45-8
h-1152 glycyl dihydrochloride
glycyl-h 1152
2-amino-1-[(3s)-3-methyl-4-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepan-1-yl]ethan-1-one
gtpl6033
SCHEMBL678400
CHEMBL3348907
NCGC00346802-02
Q27088549

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.5637AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency6.7407AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency18.9991AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency21.3174AID1645840
Interferon betaHomo sapiens (human)Potency18.9991AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency18.9991AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency18.9991AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency18.9991AID1645842

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345327Human Rho associated coiled-coil containing protein kinase 2 (Rho kinase)2005Biochimica et biophysica acta, Dec-30, Volume: 1754, Issue:1-2
ISSN: 0006-3002		Development of specific Rho-kinase inhibitors and their clinical application.
AID1345668Human aurora kinase A (Aurora kinase (Aur) family)2005Biochimica et biophysica acta, Dec-30, Volume: 1754, Issue:1-2
ISSN: 0006-3002		Development of specific Rho-kinase inhibitors and their clinical application.

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's6 (66.67)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
midodrine
0
amino acid amide;
aromatic ether;
secondary alcohol		alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent		00low000000
oxethazaine
0
amino acid amide00low000000
prilocaine
0
amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic		00low000000
qx-222
0
amino acid amide00low000000
ambucetamide
0
amino acid amide00low000000
trimecaine
0
amino acid amide00low000000
[2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium
0
amino acid amide00low000000
Phenylacetylglycine dimethylamide
0
amino acid amide00low000000
pyrrocaine
0
amino acid amide00low000000
monoethylglycinexylidide
0
amino acid amidedrug metabolite00low000000
etidocaine
0
amino acid amidelocal anaesthetic00low000000
lidofenin
0
amino acid amide00low000000
mebrofenin
0
amino acid amide00low000000
glycine amide
0
amino acid amide;
glycine derivative		00low000000
calpeptin
0
amino acid amide00low000000
glycinexylidide
0
amino acid amidedrug metabolite00low000000
N1-(4-nitrophenyl)-2-amino-3-(benzylthio)propanamide
0
amino acid amide00low000000
leucine-beta-naphthylamide
0
amino acid amide;
L-leucine derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
phenylalanine-beta-naphthylamide
0
amino acid amide;
L-phenylalanine derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
prolinamide
0
amino acid amide;
L-proline derivative;
pyrrolidinecarboxamide		00low000000
2',6'-pipecoloxylidide
0
amino acid amide00low000000
safinamide
0
amino acid amide00low000000
tyrosinamide
0
amino acid amide;
L-tyrosine derivative		00low000000
arginine beta-naphthylamide
0
amino acid amide;
L-arginine derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
3-hydroxylidocaine
0
amino acid amide00low000000
isoglutamine
0
amino acid amide;
glutamic acid derivative		00low000000
gamma-glutamyl-2-naphthylamide
0
amino acid amide;
L-glutamic acid derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
2-[carboxymethyl-[2-(2,6-diethylanilino)-2-oxoethyl]amino]acetic acid
0
amino acid amide00low000000
beta-alanine amide
0
amino acid amide00low000000
ns 105
0
amino acid amide00low000000
bortezomib
0
amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor		00low000000
tryptophanamide
0
amino acid amide;
tryptophan derivative		human metabolite00low000000
phenylalanine amide
0
amino acid amide;
phenylalanine derivative		00low000000
argininamide
0
amino acid amide;
guanidines;
L-arginine derivative		00low000000
a 80987
0
amino acid amide00low000000
2-(1,3-benzodioxol-5-ylamino)-N-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetamide
0
amino acid amide00low000000
N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-2-thiazolyl]-2-(4-morpholinyl)acetamide
0
amino acid amide00low000000
N-(1,3-benzodioxol-5-yl)-2-[4-(4-phenyl-2-thiazolyl)-1-piperazinyl]acetamide
0
amino acid amide00low000000
3-fluoro-N-[1-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-4-piperidinyl]benzamide
0
amino acid amide00low000000
N-[2-(1H-benzimidazol-2-yl)ethyl]-2-[4-(5-fluoro-1-benzotriazolyl)-1-piperidinyl]acetamide
0
amino acid amide00low000000
3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester
0
amino acid amide00low000000
2-(butan-2-ylamino)-N-[4-[5-[[2-(butan-2-ylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide
0
amino acid amide00low000000
N-[5-[[2-(4-methylanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-2-(4-morpholinyl)acetamide
0
amino acid amide00low000000
2-(butylamino)-N-[4-[5-[[2-(butylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide
0
amino acid amide00low000000
5-bromo-3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester
0
amino acid amide00low000000
3-[(3aR,6aS)-6'-chloro-5-(4-chlorophenyl)-7'-methyl-2',4,6-trioxo-1-spiro[1,2,3a,6a-tetrahydropyrrolo[3,4-c]pyrrole-3,3'-1H-indole]yl]propanamide
0
amino acid amide00low000000
2-(cyclohexylamino)-N-(4-ethylphenyl)-2-sulfanylideneacetamide
0
amino acid amide00low000000
L-histidine 2-naphthylamide
0
amino acid amide;
L-histidine derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
2-anilino-N-(4-fluorophenyl)acetamide
0
amino acid amide00low000000
N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide
0
amino acid amide;
glycine derivative		00low000000
2-(4-methyl-1-piperazinyl)-N-(5-thiophen-2-yl-1,3,4-thiadiazol-2-yl)acetamide
0
amino acid amide00low000000
N-(4-fluorophenyl)-2-[4-[oxo(1-piperidinyl)methyl]-1-piperazinyl]acetamide
0
amino acid amide00low000000
N-[4-(1,3-benzothiazol-2-yl)phenyl]-2-[(4-tert-butylphenyl)sulfonylamino]acetamide
0
amino acid amide00low000000
2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid methyl ester
0
amino acid amide00low000000
4-(5-methyl-2-furanyl)-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3-thiophenecarboxylic acid ethyl ester
0
amino acid amide00low000000
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]acetamide
0
amino acid amide00low000000
N'-(4-phenyl-2-thiazolyl)-N-(2-pyridinylmethyl)oxamide
0
amino acid amide00low000000
N'-[(4-chlorophenyl)methyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]oxamide
0
amino acid amide00low000000
N-(3-chlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide
0
amino acid amide00low000000
3-methyl-5-[[1-oxo-2-(2-pyridinylmethylamino)ethyl]amino]thiophene-2,4-dicarboxylic acid diethyl ester
0
amino acid amide00low000000
2-[2-(difluoromethoxy)anilino]-1-(2,3-dihydroindol-1-yl)ethanone
0
amino acid amide00low000000
2-(1-azepanyl)-N-[4-(dimethylsulfamoyl)phenyl]acetamide
0
amino acid amide00low000000
2-(2,3-dimethylanilino)-N-(2,3-dimethylphenyl)acetamide
0
amino acid amide00low000000
N-(3-cyano-2-thiophenyl)-2-[4-(2,5-dimethylphenyl)sulfonyl-1-piperazinyl]acetamide
0
amino acid amide00low000000
2-[[4-amino-6-(2-methylanilino)-1,3,5-triazin-2-yl]methyl-methylamino]-N-(2-ethylphenyl)acetamide
0
amino acid amide00low000000
2-(4-methyl-1-piperidinyl)-N-[2-(phenylthio)phenyl]acetamide
0
amino acid amide00low000000
N-(2-bromophenyl)-2-[[2-(2,6-dimethylanilino)-2-oxoethyl]-methylamino]acetamide
0
amino acid amide00low000000
N-(4-cyano-1-phenyl-1H-pyrazol-5-yl)-2-(4-methylpiperazino)acetamide
0
amino acid amide00low000000
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide
0
amino acid amide00low000000
N'-[4-(1-adamantyl)-2-thiazolyl]-N-[(4-fluorophenyl)methyl]oxamide
0
amino acid amide00low000000
N-(3-chloro-4-methylphenyl)-2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)acetamide
0
amino acid amide00low000000
N-(4-nitrophenyl)-2-(1-pyrrolidinyl)acetamide
0
amino acid amide00low000000
2-(benzenesulfonamido)-N-[(2-methoxyphenyl)methyl]propanamide
0
amino acid amide00low000000
N-cycloheptyl-2-(cyclohexylamino)-2-sulfanylideneacetamide
0
amino acid amide00low000000
6-methyl-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester
0
amino acid amide00low000000
N'-[4-(dimethylamino)phenyl]-N-propyloxamide
0
amino acid amide00low000000
N-tert-butyl-2-[[(3-nitrophenyl)-oxomethyl]hydrazo]-2-oxoacetamide
0
amino acid amide00low000000
2-[[2-(4-chlorophenoxy)-1-oxoethyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide
0
amino acid amide00low000000
2-[[2-(2,4-dichlorophenoxy)-1-oxopropyl]hydrazo]-N-(4-methoxyphenyl)-2-oxoacetamide
0
amino acid amide00low000000
2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide
0
amino acid amide00low000000
N-(3-fluorophenyl)-2-oxo-4,10-dihydro-3H-pyrimido[1,2-a]benzimidazole-4-carboxamide
0
amino acid amide00low000000
N-[2-(cyclopentylamino)-2-oxoethyl]-4,7-dimethyl-N-(2-methylphenyl)-2-oxo-3H-pyrido[1,2-a]pyrimidine-4-carboxamide
0
amino acid amide00low000000
N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-5-methyl-2-thiazolyl]-2-(4-morpholinyl)acetamide
0
amino acid amide00low000000
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(1-phenylethyl)acetamide
0
amino acid amide00low000000
N-[2-(2-ethyl-1-piperidinyl)ethyl]-2-[(2-methyl-1,3-benzothiazol-6-yl)sulfonylamino]acetamide
0
amino acid amide00low000000
1-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxo-1-phenylethyl]-4-piperidinecarboxylic acid ethyl ester
0
amino acid amide00low000000
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide
0
amino acid amide00low000000
N-(1,3-benzodioxol-5-yl)-2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]acetamide
0
amino acid amide00low000000
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(3-pyridinylmethyl)acetamide
0
amino acid amide00low000000
2-[4-[2-(3,5-dimethoxyanilino)-2-oxoethyl]-1-piperazinyl]-N-(4-ethoxyphenyl)acetamide
0
amino acid amide00low000000
N-(4-methoxyphenyl)-2-(N-methylanilino)-2-(6-nitro-1,3-benzodioxol-5-yl)acetamide
0
amino acid amide00low000000
2-[[2-[(2,5-dimethylphenyl)sulfonylamino]-1-oxoethyl]amino]-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
0
amino acid amide00low000000
N-decyl-N'-(2-pyridinyl)oxamide
0
amino acid amide00low000000
3-(3-bromoanilino)-2-oxo-1H-indole-3-carbonitrile
0
amino acid amide00low000000
N-(1,3-benzothiazol-2-yl)-2-ethylsulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide
0
amino acid amide00low000000
N-cyclopentyl-2-(2,3-dihydroindol-1-yl)-2-(4-methoxyphenyl)acetamide
0
amino acid amide00low000000
2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide
0
amino acid amide00low000000
N-[4-chloro-3-(dimethylsulfamoyl)phenyl]-2-[(phenylmethyl)amino]acetamide
0
amino acid amide00low000000
N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-(2-fluorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide
0
amino acid amide00low000000
2-anilino-N-(4-methylphenyl)-2-phenylacetamide
0
amino acid amide00low000000
2-anilino-N-(3,5-dimethylphenyl)-2-phenylacetamide
0
amino acid amide00low000000
N-(3-chloro-2-methylphenyl)-2-[3-(dimethylsulfamoyl)anilino]acetamide
0
amino acid amide00low000000
2-(5-chloro-2,4-dimethoxyanilino)-1-(4-ethyl-1-piperazinyl)-1-propanone
0
amino acid amide00low000000
2-(2-chloro-4-methylanilino)-N-[3-(dimethylsulfamoyl)phenyl]acetamide
0
amino acid amide00low000000
N-(2,5-difluorophenyl)-2-(1-pyrrolidinyl)acetamide
0
amino acid amide00low000000
N-(2-bromophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide
0
amino acid amide00low000000
N-(3-chloro-4-fluorophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide
0
amino acid amide00low000000
N-(4-bromo-2-fluorophenyl)-2-(2,4-dimethoxyanilino)acetamide
0
amino acid amide00low000000
LSM-24595
0
amino acid amide00low000000
5-carbamoyl-4-methyl-2-[[1-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester
0
amino acid amide00low000000
N-[(4-chlorophenyl)methyl]-2-[[[(2-fluorophenyl)methyl-(phenylmethyl)amino]-sulfanylidenemethyl]amino]acetamide
0
amino acid amide00low000000
N-(1,3-benzodioxol-5-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide
0
amino acid amide00low000000
N-[2-chloro-5-[ethyl(phenyl)sulfamoyl]phenyl]-2-[methyl-(1-methyl-4-piperidinyl)amino]acetamide
0
amino acid amide00low000000
3,4-dihydro-1H-isoquinolin-2-yl-[1-(8-quinolinylsulfonyl)-2-pyrrolidinyl]methanone
0
amino acid amide00low000000
1-(4-tert-butylphenyl)sulfonyl-N-(2-pyridinylmethyl)-2-piperidinecarboxamide
0
amino acid amide00low000000
(3S,3'aR,8'aS,8'bS)-5-ethyl-2'-(phenylmethyl)spiro[1H-indole-3,4'-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1',2,3'-trione
0
amino acid amide00low000000
cefatrizine
0
amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor		00low000000
N-(1,3-benzothiazol-2-yl)-2-(2,6-dimethyl-4-morpholinyl)acetamide
0
amino acid amide00low000000
N-(3,4-dichlorophenyl)-2-[4-(1-piperidinylsulfonyl)-1-piperazinyl]acetamide
0
amino acid amide00low000000
iprovalicarb
0
amino acid amide;
carbamate ester;
valine derivative		00low000000
vildagliptin
0
amino acid amide00low000000
(3aR,4S,9aR,9bS)-N,2-bis(4-chlorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide
0
amino acid amide00low000000
eluxadoline
0
amino acid amide;
benzamides;
imidazoles;
L-phenylalanine derivative;
methoxybenzoic acid		delta-opioid receptor antagonist;
gastrointestinal drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist		00low000000
gosogliptin
0
amino acid amide00low000000
teneligliptin
0
amino acid amide00low000000
2-[(5-bromo-2-thiophenyl)sulfonylamino]-N-cyclopentyl-2-phenylacetamide
0
amino acid amide00low000000
N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)oxamide
0
amino acid amide00low000000
2-[1-[(2-chloro-6-fluorophenyl)methyl]-3-oxo-2-piperazinyl]-N-prop-2-enylacetamide
0
amino acid amide00low000000
aspartic acid beta-naphthylamide
0
amino acid amide;
L-aspartic acid derivative;
N-(2-naphthyl)carboxamide		chromogenic compound00low000000
(3aR,4S,9aR,9bS)-N-(4-chlorophenyl)-2-(4-fluorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide
0
amino acid amide00low000000
N-[[3-(4-nitrophenyl)sulfonyl-2-oxazolidinyl]methyl]-N'-(2-pyridinylmethyl)oxamide
0
amino acid amide00low000000
Majusculamide AB
0
amino acid amidemetabolite00low000000
anagliptin
0
amino acid amide00low000000
1-(4-methyl-1-piperazinyl)-2-[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]ethanone
0
amino acid amide00low000000
bactobolin
0
amino acid amide00low000000
N-(1,3-benzodioxol-5-yl)-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide
0
amino acid amide00low000000
2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-[2-(methylthio)phenyl]acetamide
0
amino acid amide00low000000
2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-(3-fluorophenyl)acetamide
0
amino acid amide00low000000
N-[2-(4-chlorophenyl)ethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide
0
amino acid amide00low000000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0
1
202020204.0high000010
Disease Models, Animal0
1
202020204.0high000010
Zika Virus Infection0
1
202020204.0high000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019